# STRIDE - STimulating Immune Response In aDvanced brEast Cancer

> **NCT00925548** · PHASE3 · TERMINATED · sponsor: **EMD Serono** · enrollment: 16 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Tecemotide (L-BLP25) and Hormonal Treatment
- **BIOLOGICAL:** Placebo of tecemotide (L-BLP25) and Hormonal Treatment
- **DRUG:** cyclophosphamide
- **DRUG:** sodium chloride (NaCl)

## Key facts

- **NCT ID:** NCT00925548
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** See termination reason in the below Purpose statement
- **Last updated:** 2014-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925548, "STRIDE - STimulating Immune Response In aDvanced brEast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00925548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*